Navigation Links
Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
Date:12/1/2011

xpeditious regulatory review and marketing clearance.

The Company also announced today that the next investor conference call, initially scheduled for late November, will be rescheduled to early January, 2012.  "The Generex management team and its advisors have been working diligently on the previously announced strategic development plan, including the spinout of Antigen Express, the Generex reverse stock split, the stock dividends of Antigen stock to the Generex stockholders, and the clinical and regulatory development programs for Generex Oral-lyn™ and the the AE37 immuno-therapuetic vaccines platform technologies, and significant progress has been made," said Mark Fletcher, the Generex President & Chief Executive Officer.  "In order that the investor conference call will be as productive, informative, and useful as possible, we have elected to reschedule the call to a later date when the plan will have achieved greater maturity and specificity so as to be in a position to provide a more comprehensive and detailed report to our stockholders."

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy.  One of i
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
2. Generex Provides Update on Spinout of Antigen Express
3. Generex Augments Cash Position With Sales of Non-Essential Assets
4. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
5. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
6. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
7. Generex Provides Clarification of Facts
8. Generex Announces Results of Annual Stockholders Meeting
9. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
10. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
11. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Nasseo, Inc. today announces that it has ... hundreds of applicants by the Arizona Commerce Authority ... . The Arizona Innovation Challenge (AIC) awards the most ... granting a financial award to what it deems to ... of the art dental and orthopedic implant surface modification ...
(Date:6/18/2013)... June 18, 2013  AMRI (NASDAQ: ... Burlington, Mass. , site has received approval ... (DEA) registration to handle Schedule 2 and 2N ... of Burlington,s physical security ... (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ...
(Date:6/18/2013)... , June 18, 2013 ... has announced the addition of the report ... Companies " to their offering. ... briefly reviews basics of human genome variations, ... Current large and small sequencers are described ...
(Date:6/18/2013)... WA (PRWEB) June 18, 2013 Though ... -- 11,000, according to the U.S. Bureau of Labor Statistics ... increase of 24,000 per month. Most new health care jobs ... the hospital sector saw a loss of 6,000 jobs. Overall, ... outplacement consultancy firm Challenger, Gray & Christmas reported that a ...
Breaking Biology Technology:Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 2MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 3
... China, April 4, 2008 /Xinhua-PRNewswire-FirstCall/ -- WuXi,PharmaTech ... PharmaTech"), a leading,pharmaceutical, biotechnology and medical device ... China and the United States, today,announced that ... Form F-1 with the,Securities and Exchange Commission ...
... April 4, 2008 Scientists in fields,as diverse ... from the Olympus FluoroPoint(TM) single molecule fluorescence,detection system ... of laboratories around the world, the system, with ... of use, is now,available for the first time ...
... (Nasdaq: IDMI ) announced today the appointment of ... 3, 2008. Mr. Tibbitts is,currently the chief financial officer ... medical device company and in this role has overseen ... as from a clinical,stage company to the current commercial ...
Cached Biology Technology:WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering 2Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research 2Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research 3IDM Pharma Appoints Gregory J. Tibbitts to Board of Directors 2IDM Pharma Appoints Gregory J. Tibbitts to Board of Directors 3
(Date:6/17/2013)... French . A ... Alzheimer,s disease can be reversed with treatment. The study by ... Neuro, at McGill University and at Universit de Montral found ... brain of mice with advanced Alzheimer,s disease (AD) recovers memory ... of Neuroinflammation in May, also suggest an underlying mechanism ...
(Date:6/16/2013)... together and move around the body called ,chase and ... scientists at UCL. , Published in Nature Cell ... occurs when cancer cells interact with healthy cells in order ... cancer cells recruit healthy cells and use them to travel ... it could be controlled to design new therapies against cancer ...
(Date:6/14/2013)... students have difficulty understanding and explaining how evolution ... the subject, researchers at Michigan State University developed ... the molecular changes underlying an evolving characteristic to ... researchers, Peter J. T. White, Merle K. Heidemann, ... the scenarios into a cellular and molecular biology ...
Breaking Biology News(10 mins):Blocking overactive receptor in Alzheimer's recovers memory loss and more 2'Chase and run' cell movement mechanism explains process of metastasis 2Teaching complete evolutionary stories increases learning 2
... Biotechnology and Biological Sciences Research Council (BBSRC) at the University ... explain why the earliest evidence of complex multicellular animal life ... on the planet rose sharply from 3% to their modern ... Chris Schofield, has found that humans share a method of ...
... indicates an increased risk for developing breast cancer can ... according to a new study featuring work from researchers ... and their colleagues. The multidisciplinary team found that ... more likely to be present in breast cancer patients ...
... 2010) Whitehead Institute Founding Member Rudolf Jaenisch has been ... Massachusetts General Hospital (MGH). By tradition, the ... the prize with Dr. Shinya Yamanaka, who is on the ... Institutes in San Francisco. "The Warren Prize is the ...
Cached Biology News:550 million years ago rise in oxygen drove evolution of animal life 2Key information about breast cancer risk and development is found in 'junk' DNA 2Key information about breast cancer risk and development is found in 'junk' DNA 3Whitehead Member Rudolf Jaenisch to receive MGH's Warren Triennial Prize 2
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Anti (porcine) Vitronectin...
... to work in collaboration with Pall Life ... filters in a variety of membrane chemistries. ... use on the Caliper TPWII, MultiDose, Prelude, ... for our Automation Certified Syringe Filters are ...
... to BMP2 BMP2 belongs to ... superfamily. Bone morphogenic protein induces bone ... for the autosomal dominant disease of ... Immunogen: Synthetic peptide: PSDEVLSEFELRLLSM conjugated ...
Biology Products: